



# **ESME**

## **Cancer du Sein Métastatique**

**Publications  
référéncées dans PubMed**

Direction Datas et Partenariats

## Publications 2016

---

1. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study  
Delaloge S, Perol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C.  
Ann Oncol. 2016 Sep;27(9):1725-32. <https://doi.org/10.1093/annonc/mdw260>
2. Routinely collected data may usefully supplement Randomised controlled data on treatment effects for mortality  
Pérol D, Robain M, Delaloge S, Cailliot C.  
BMJ. 2016 Dec 16;355:i6745. <https://doi.org/10.1136/bmj.i6745>

## Publications 2018

---

3. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2–negative metastatic breast cancer patients.  
Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delaloge S, Debled M, Vanlemmens L, Leheurteur M, Guizard AV, Laborde L, Uwer L, Jacot W, Berchery D, Desmoulin I, Ferrero JM, Perrocheau G, Courtinard C, Brain E, Chabaud S, Robain M, Bachelot T.  
Eur J Cancer. 2018 May;95:93-101. <https://doi.org/10.1016/j.ejca.2018.03.013>
4. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.  
Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Lardy-Cleaud A, Robain M, Courtinard C, Cailliot C, Perol D, Delaloge S.  
Eur J Cancer. 2018 Jun;96:17-24. <https://doi.org/10.1016/j.ejca.2018.03.015>

## Publications 2019 (1/3)

---

5. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.  
Cabel L, Carton M, Cheaib B, Pierga J-Y, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Perol D, Simon G, Lerebours F.  
Breast Cancer Res Treat. 2019 Jan;173(2):397-406. <https://doi.org/10.1007/s10549-018-5017-2>
6. Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.  
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Mazouni C, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Goncalves A, Jankowski C, De La Motte Rouge T, Pouget N, La Lande B, Mouttet-Boitat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Robain M, Filleron T, Cailliot C, Dalenc F.  
Ann Surg Oncol. 2019 Feb;26(2):356-65. <https://doi.org/10.1245/s10434-018-6831-9>
7. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)  
Perol D, Robain M, Arveux P, Mathoulin-Pelissier S, Chamorey E, Asselain B, Berchery D, Gourgou S, Breton M, Delaine-Clisant S, Mons M, Dieras V, Carton M, Guizard AV, Laborde L, Laurent C, Loeb A, Mouret-Reynier MA, Parent D, Perrocheau G, Campion L, Velten M, Cailliot C, Ezzalfani M, Simon G.  
BMJ Open. 2019 Feb 21;9(2):e023568. <https://doi.org/10.1136/bmjopen-2018-023568>

## Publications 2019 (2/3)

---

8. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. Petitjean A, Smith-Palmer J, Valentine W, Tehard B, Roze S. BMC Cancer. 2019 Feb 11;19(1):140. <https://doi.org/10.1186/s12885-019-5335-8>
9. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, Vanlemmens L, Leheurteur M, Levy C, Laborde L, Uwer L, D'hont V, Berchery D, Lorgis V, Ferrero JM, Perrocheau G, Courtinard C, Mouret-Reynier MA, Velten M, Breton M, Parent D, Chabaud S, Robain M, Bachelot T. Eur J Cancer. 2019 Sep;118:131-41. <https://doi.org/10.1016/j.ejca.2019.06.014>
10. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. Gougis P, Carton M, Tchokothe C, Campone M, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Bachelot T, Hennequin A, Perrin C, Goncalves A, Uwer L, Eymard JC, Mouret-Reynier MA, Chamorey E, Dimon G, Saghatchian M, Cailliot C, Le Tourneau C. Breast. 2019 Oct 30;49:17-24. <https://doi.org/10.1016/j.breast.2019.10.004>

## Publications 2019 (3/3)

---

11. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.  
Jacot W, Heudel P, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A.  
Int J Cancer. 2019 Dec 15;145(12):3359-69. <https://doi.org/10.1002/ijc.32402>
12. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.  
Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Delaloge S, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Chevrot M, Pasquier D, Bachelot T.  
Br J Cancer. 2019 Dec;121(12):991-1000. <https://doi.org/10.1038/s41416-019-0619-y>

## Publications 2020 (1/3)

---

13. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.  
Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier MA, Goncalves A, Dalenc F, Deluche E, Frenel JS, Augereau P, Ferrero JM, Geffrelot J, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Mouttet-Audouard R, Bachelot T, Courtinard C.  
Eur J Cancer. 2020 Jan;125:22–30. <https://doi.org/10.1016/j.ejca.2019.11.001>
14. Radiation Therapy to the Primary Tumor for de Novo Metastatic Breast Cancer and Overall Survival in a Retrospective Multicenter Cohort Analysis.  
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Rivera S, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Goncalves A, Jankowski C, De La Motte Rouge T, Pouget N, De la Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Courtinard C, Filleron T, Robain M, Dalenc F.  
Radiother and Oncol. 2020 Apr;145:109-16. <https://doi.org/10.1016/j.radonc.2019.12.019>
15. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.  
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Courtinard C, Perol D, Robain M, Delaloge S.  
Eur J Cancer. 2020 Apr;129:60-70. <https://doi.org/10.1016/j.ejca.2020.01.016>

## Publications 2020 (2/3)

---

16. Real-World Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.  
Heudel P, Delaloge S, Parent D, Madranges N, Levy C, Dalenc F, Brain E, Uwer L, D'hont V, Augereau P, Mailliez A, Perrin C, Frenel JS, Sablin MP, Mouret-Reynier MA, Vermeulin T, Eymard JC, Petit T, Ferrero JM, Ilie S, Goncalves A, Chenuc G, Robain M, Simon G, Perol D. Anticancer Res. 2020 Jul;40(7):3905-13. <https://doi.org/10.21873/anticancer.14381>
17. Impact of Age at Diagnosis of Metastatic Breast Cancer on Overall Survival in the Real-Life ESME Metastatic Breast Cancer Cohort.  
Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'hont V, Debled M, Vermeulin T, Coudert B, Perrin C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Patsouris A, Guesmia T, Bachelot T, Robain M, Cottu P. The Breast. 2020 Aug;52:50-57. <https://doi.org/10.1016/j.breast.2020.04.009>
18. Palliative Care Delivery According to Age in 12,000 Women with Metastatic Breast Cancer: Analysis in the Multicentre ESME-MBC Cohort 2008–2016.  
Frasca M, Sabathe C, Delaloge S, Galvin A, Patsouris A, Levy C, Mouret-Reynier MA, Desmoulins I, Vanlemmes L, Bachelot T, Goncalves A, Perotin V, Uwer L, Frenel JS, Ferrero JM, Bouleuc C, Eymard JC, Dieras V, Leheurteur M, Petit T, Dalenc F, Jaffre A, Chevrot M, Courtinard C, Mathoulin-Pelissier S. Eur J Cancer. 2020 Sep;137:240-49. <https://doi.org/10.1016/j.ejca.2020.07.007>

## Publications 2020 (3/3)

---

19. Management and Outcome of Male Metastatic Breast Cancer in the National Multicenter Observational Research Program Epidemiological Strategy and Medical Economics (ESME). Sirieux J, Fraisse J, Mathoulin-Pelissier S, Leheurteur M, Vanlemmens L, Jouannaud C, Dieras V, Levy C, Ung M, Mouret-Reynier MA, Petit T, Coudert B, Brain E, Pistilli B, Ferrero JM, Goncalves A, Uwer L, Patsouris, Tredan O, Courtinard C, Gourgou S, Frenel JS. Ther Adv Med Oncol 2020 Dec 23;12. <https://doi.org/10.1177/1758835920980548>

## Publications 2021 (1/4)

---

20. Real-Life Prognosis of 5041 Bone-Only Metastatic Breast Cancer Patients in the Multicenter National Observational ESME Program.  
Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Perol D, Jaffre A, Goncalves A, Lebitasy MP, D'hont V, Dalenc F, Ferrero JM, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard JC, Breton M, Chevrot M, Thureau S, Petit T, Simon G, Frenel JS.  
Ther Adv Med Oncol 2021 Jan;13. <https://doi.org/10.1177/1758835920987657>
21. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.  
Hotton J, Lusque A, Leufflen L, Campone M, Levy C, Honart JF, Mailliez A, Debled M, Gutowski M, Leheurteur M, Goncalves A, Jankowski C, Guillermet S, Bachelot T, Ferrero JM, Eymard JC, Petit T, Pouget N, De la Lande B, Frenel JS, Villacroux O, Simon G, Pons-Tostivint E, Marchal F.  
Ann Surg. 2021 Jan;277(1):e153-61. <https://doi.org/10.1097/sla.0000000000004767>
22. Impact of body mass index on overall survival in patients with metastatic breast cancer.  
Saleh K, Carton M, Dieras V, Heudel P-E, Brain E, D'hondt V, Mailliez A, Patsouris A, Mouret-Reynier MA, Goncalves A, Ferrero JM, Petit T, Emile G, Uwer L, Debled M, Dalenc F, Jouannaud C, Ladoire S, Leheurteur M, Cottu P, Veron L, Savignoni A, Courtinard C, Robain M, Delalogue S, Deluche E.  
Breast. 2021 Feb;55:16–24. <https://doi.org/10.1016/j.breast.2020.11.014>

## Publications 2021 (2/4)

---

23. Outcome beyond third-line chemotherapy for metastatic triple negative breast cancer in the French ESME program.  
Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemmens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De La Motte Rouge T, Laborde L, Laurent C, Chalorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreveux C, Bachelot T, Robain M, Lerebours F.  
The Breast. 2021 Apr; 56:18-25. <https://doi.org/10.1016/j.breast.2021.01.006>
24. Phenotypic Discordance between Primary and Metastatic Breast Cancer in the Large-Scale Real-Life Multicenter French ESME Cohort.  
Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F, Macgrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzales A, Charafe-Jauffret E, Courtinard C, Franchet C, Verrielle V, Brain E, Tas P, Blanc-Fournier C, Leroux A, Lousouarn D, Berghian A, Brabencova E, Ghassia JP, Scoazec JY, Delaloge S, Filleron T, Lacroix-Tikri M.  
NPJ Breast Cancer. 2021 Apr;7(1):41. <https://doi.org/10.1038/s41523-021-00252-6>
25. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.  
Carausu M, Carton M, Darlix A, Pasquier D, Leheurteur M, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Verret B, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lefeuvre-Plesse C, Petit T, Uwer L, Jouannaud C, Larrouquere L, Chevrot M, Courtinard C, Cabel L.  
ESMO Open. 2021 Jun;6(3):100150. <https://doi.org/10.1016/j.esmoop.2021.100150>

## Publications 2021 (3/4)

---

26. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.  
Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Diéras V, Dalenc F, Goncalves A, Debled M, Patsouris, Mouret-Reynier MA, Mailliez A, Clatot F, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Tokri M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Perol D, Delalogue S.  
ESMO Open. 2021 Jun;6(3):100114. <https://doi.org/10.1016/j.esmoop.2021.100114>
27. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national and real-life French cohort (ESME).  
Dano D, Lardy-Cléaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, De La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Goncalves A.  
ESMO Open. 2021 Aug;6(4):100220. <https://doi.org/10.1016/j.esmoop.2021.100220>
28. Addressing the Issue of Bias in Observational Studies: Using Instrumental Variables and a Quasi-Randomization Trial in an ESME Research Project.  
Ezzalfani M, Porcher R, Savignoni A, Delalogue S, Filleron T, Robain M, Perol D, ESME Group.  
PLoS One. 2021 Sep;16(9): e0255017. <https://doi.org/10.1371/journal.pone.0255017>

## Publications 2021 (4/4)

---

29. De Novo Metastatic Breast Cancer in Patients with a Small Locoregional Tumour (T1-T2/N0): Characteristics and Prognosis.  
Gaillard T, Carton M, Mailliez A, Desmoulins I, Mouret-Reynier MA, Petit T, Leheurteur M, Dieras V, Ferrero JM, Uwer L, Guiu S, Goncalves A, Levy C, Debled M, Dalenc F, Patsouris A, Bachelot T, Eymard JC, Chevrot M, Conversano A, Robain M, Hequet D.  
Eur J Cancer. 2021 Oct; 158:181-8. <https://doi.org/10.1016/j.ejca.2021.09.021>
30. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database.  
Annonay M, Gauquelin L, Geiss R, Ung M, Cristol-Dalstein L, Mouret-Reynier MA, Goncalves A, Abadie-Lacourtoisie S, François E, Perrin C, Le Fel J, Lorgis V, Servent V, Uwer L, Jouannaud C, Leheurteur M, Joly F, Champion L, Courtinard C, Villacroux O, Petit T, Soubeyran P, Terret C, Bellera C, Brain E, Delaloge S.  
The Breast. 2021 Dec;60:138-46. <https://doi.org/10.1016/j.breast.2021.09.011>

## Publications 2022 (1/3)

---

31. Progression free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.  
Corbaux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, Lévy C, Viansone AA, Mailliez A, Debled M, Goncalves A, Le Du F, Lerebours F, Ferrero JM, Eymard JC, Mouret-Reynier MA, Petit T, Frenel JS, Dalenc F, Courtinard C, Chaix M, Bachelot T.  
Breast Cancer Res Treat. 2022 Jan;191(1):191. <https://doi.org/10.1007/s10549-021-06382-6>
32. Real-World Evidence of the Management and Prognosis of Young Women ( $\leq 40$  Years) with de Novo Metastatic Breast Cancer.  
Mallet A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Goncalves A, Desmoulins I, De la Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Cottu P, Dalenc F, Petit T, Payen O, Uwer L, Guiu S, Frenel JS.  
Ther Adv Med Oncol. 2022 Jan;14. <https://doi.org/10.1177/17588359211070362>
33. Clinicopathological Characteristics and Prognosis of Breast Cancer Patients with Isolated Central Nervous System Metastases in the Multicentre ESME Database.  
Carausu M, Carton M, Cabel L, Patsouris A, Levy C, Verret B, Pasquier D, Debled M, Goncalves A, Desmoulins I, Lecouillard I, Bachelot T, Ferrero JM, Eymard JC, Mouret-Reynier MA, Chevrot M, De Maio E, Uwer L, Frenel JS, Leheuteur, Petit T, Darlix A, Bozec L.  
Ther Adv Med Oncol. 2022 Feb;14. <https://doi.org/10.1177/17588359221077082>

## Publications 2022 (2/3)

---

34. Enrollment of Older Metastatic Breast Cancer Patients in First-Line Clinical Trials: 9-Year Experience of the Large-Scale Real-Life Multicenter French ESME Cohort.  
Bringuier M, Carton M, Levy C, Patsouris A, Pasquier D, Debled M, *et al.* Breast Cancer Res Treat. 2022 Feb;191(3):577-87. <https://doi.org/10.1007/s10549-021-06467-2>
35. Impact of Lobular versus Ductal Histology on Overall Survival in Metastatic Breast Cancer: A French Retrospective Multicentre Cohort Study.  
Dalenc F, Lusque A, De La Motte Rouge T, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Goncalves A, Desmoulins I, Levy C, Uwer L, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Frenel JS, Petit T, Chevrot M, Bachelot T, Guiu S.  
Eur J Cancer. 2022 Mar;164: 70–9. <https://doi.org/10.1016/j.ejca.2021.12.031>
36. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.  
Moinard-Butot F, Saint-Martin C, Pflumio C, Carton M, Jacot W, Cottu PH, Dieras V, Dalenc F, Goncalves A, Debled M, Patsouris A, Mouret-Reynier MA, Vanlemmens L, Leheurteur M, Emile G, Ferrero JM, Desmoulins I, Uwer L, Eymard JC, Cheaib B, Courtinard C, Bachelot T, Chevrot M, Petit T.  
The Breast. 2022 Mar;164:70–9. <https://doi.org/10.1016/j.ejca.2021.12.031>

## Publications 2022 (3/3)

---

37. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.  
De Calbiac O, Lusque A, Maillez A, Bachelot T, Uwer L, Mouret-Reynier MA, Emile G, Jouannaud C, Goncalves A, Patsouris A, Dieras V, Leheurteur M, Petit T, Cottu P, Ferrero JM, D'hont V, Desmoulins I, Mourato-Ribeiro J, Martin AL, Frenel JS  
JAMA Network Open. 2022 Sep; 5(9):e2231170.  
<https://doi.org/10.1001/jamanetworkopen.2022.31170>
38. Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane.  
Vasseur A, Carton M, Guiu S, Augereau P, Uwer L, Mouret-Reynier MA, Levy C, Eymard JC, Ferrero JM, Leheurteur M, Goncalves A, Robert M, De la Motte Rouge T, Bachelot T, Petit T, Debled M, Grinda T, Desmoulins I, Vanlemmens L, Nicolai V, Simon G, Cabel L.  
The Breast. 2022 Oct;65:136-44. <https://doi.org/10.1016/j.breast.2022.07.014>
39. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.  
Jacot W, Lusque A, Vicier C, Maillez A, De la Motte Rouge T, Cabel L, Levy C, Patsouris A, Desmoulins I, Uwer L, Thery JC, Robain M, Caron O, Tredan O, Filleron T, Frenel JS, Delaloge S.  
Br J Cancer. 2022 Nov;127(11):1963-73. <https://doi.org/10.1038/s41416-022-02003-1>

## Publications 2022 (3/3)

---

40. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.  
Carausu M, Carton M, Dieras V, Petit T, Guiu S, Goncalves A, Augereau P, Ferrero JM, Levy C, Ung M, Desmoulins I, Debled M, Bachelot T, Pistilli B, Frenel JS, Mailliez A, Chevrot M, Cabel L. *JAMA Network Open*. 2022 Dec; 5(12):e2247154.  
<https://doi.org/10.1001/jamanetworkopen.2022.47154>

## Publications 2023 (1/3)

---

41. Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.  
François-Martin H, Lardy-Cléaud A, Pistilli B, Levy C, Dieras V, Frenel JS, Guiu S, Mouret-Reynier MA, Mailliez A, Eymard JC, Petit T, Ung M, Desmoulins I, Augereau P, Bachelot T, Uwer L, Debled M, Ferrero JM, Caltot F, Goncalves A, Chevrot M, Chabaud S, Cottu P. Cancer. 2023 Feb;15(4):1191. <https://doi.org/10.3390/cancers15041191>
42. Survival outcome of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.  
Mailliez A, D'hont V, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero JM, Petit T, Mouret-Reynier MA, Eymard JC, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Frenel JS, De la Motte Rouge T, Simon G, Jacot W, Delaloge S. Int J Cancer. 2023 Mar;152(5):921-31. <https://doi.org/10.1002/ijc.34304>
43. Clinical outcome of patients with isolated central nervous system progression on first-line Pertuzumab and Trastuzumab treatment for HER2-positive metastatic breast cancer in real life cohort.  
Collet L, Eberst L, Gauthier L, Debled M, Hrab I, Mouret-Reynier MA, Desmoulins I, Goncalves A, Campone M, Ferrero JM, Brain E, Uwer L, Eymard JC, Dieras V, Simon G, Leheurteur M, Dalenc F, Vanlemmens L, Darlix A, Arnedos M, Bachelot T. Breast Cancer. 2023 Mar;30(2):329-41. <https://doi.org/10.1007/s12282-022-01427-0>

## Publications 2023 (2/3)

---

44. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.  
Courtinard C, Gourgou S, Jacot W, Carton M, Guérin O, Vacher L, Bertaut A, Le Deley MC, Perol D, Marino P, Levy C, Uwer L, Perrocheau G, Schiappa R, Bachelot F, Parent D, Breton M, Petit T, Filleron T, Loeb A, Mathoulin-Pelissier S, Robain M, Delaloge S, Bellera C.  
BMC Med. 2023 Mar;21(1):87 <https://doi.org/10.1186/s12916-023-02754-5>
45. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with BRCA1/2 mutation.  
Frenel JS, Lusque A, Delaloge S, Ferrero JM, Bachelot T, Desmoulins I, Levy C, Eymard JC, Goncalves A, Patsouris A, Mouret-Reynier MA, Thery JC, Petit T, Cabel L, Uwer L, Chevrot M, Mailliez A, Jacot W, De la Motte Rouge T.  
Br J Cancer. 2023 Jun;128(11):2072-80. <https://doi.org/10.1038/s41416-023-02248-4>
46. Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort.  
Antoine A, Pérol D, Robain M, Delaloge S, Lasset C, Drouet Y.  
JNCI. 2023 Aug;115(8):971-80. <https://doi.org/10.1093/jnci/djad092>

## Publications 2023 (3/3)

---

47. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.  
Grinda T, Antoine A, Jacot W, Cottu PH, De la Motte Rouge T, Frenel JS, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret-Reynier MA, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Perol D, Pistilli B, Delaloge S.  
Eur J Cancer. 2023 Aug;1189:112935 <https://doi.org/10.1016/j.ejca.2023.05.023>
48. Real-world impact of adjuvant anti-HER2 treatment on characteristics and outcomes of women with HER2-positive metastatic breast cancer in the ESME program.  
Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, Loirat D, Vanlemmens L, Vermeuin T, Emile G, Goncalves A, Ung M, Robert M, Jaffre A, Desmoulins I, Jouannaud C, Uwer L, Ferrero JM, Mouret-Reynier MA, Jacot W, Chevrot M, Delaloge S, Dieras V.  
The Oncologist. 2023 Aug;137 <https://doi.org/10.1093/oncolo/oyad137>
49. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.  
Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, Arnedos M, Bailleux C, Dieras V, Petit T, Emile G, Dubray-Longeras P, Frenel JS, Bachelot T, Mailliez A, Brain E, Desmoulins I, Massard V, Patsouris A, Goncalves A, Grinda T, Delaloge S, Bellera C.  
Eur J Cancer. 2023 Nov;196 <https://doi.org/10.1016/j.ejca.2023.113422>